EcoDrugPlus

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSDARG00000005941
Gene Symbol: YES1
5 Cross references
197 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSDARG00000031796
Gene Symbol: ACHE
5 Cross references
234 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSDARG00000044422
Gene Symbol: ACVR2BA
5 Cross references
194 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSDARG00000103108
Gene Symbol: LOC100331938
4 Enzyme and pathways 5 Cross references
196 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSDARG00000075694
Gene Symbol: ADORA1B
8 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSDARG00000033706
Gene Symbol: ADORA2AA
10 Enzyme and pathways 5 Cross references
188 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSDARG00000002533
Gene Symbol: ADORA2B
10 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Adenosine A4 Receptor A

Ensembl ID : ENSDARG00000044061
Gene Symbol: ADORA4A
8 Enzyme and pathways 5 Cross references
221 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSDARG00000003113
Gene Symbol: ADA
4 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSDARG00000026246
Gene Symbol: LOC571410
8 Enzyme and pathways 5 Cross references
212 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSDARG00000070056
Gene Symbol: LOC100007535
8 Enzyme and pathways 4 Cross references
208 Possible Orthologues:

Adhesion Regulating Molecule 1

Ensembl ID : ENSDARG00000058560
Gene Symbol: ADRM1
5 Enzyme and pathways 5 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).